Physician profile
Diane Kim
NPI 1598150716
$3,703.54
in general payments reported to CMS, 2019-2025
20 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $378 · 2022: $125 · 2023: $425 · 2024: $1,397 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,930 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.94 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.50 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.89 | 2019-2024 | Jardiance |
| Amgen INC. | $499.72 | 2019-2024 | Evenity |
| Astrazeneca Pharmaceuticals LP | $423.31 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $203.25 | 2019-2020 | |
| Novo Nordisk INC | $200.32 | 2019-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $167.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $157.17 | 2019-2020 | |
| Lilly USA, LLC | $154.65 | 2023 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $123.76 | 2024 | Voquezna |
| Neurocrine Biosciences, INC. | $113.50 | 2024 | Ingrezza |
| Amarin Pharma, INC. | $65.49 | 2019 | |
| Merck Sharp & Dohme LLC | $56.19 | 2019 | |
| Astellas Pharma US INC | $52.55 | 2019 | |
| Allergan, INC. | $35.76 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $25.00 | 2024 | Nourianz |
| Celgene Corporation | $19.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.44 | 2019 | |
| Glaxosmithkline, LLC. | $14.96 | 2019 | |
| Melinta Therapeutics, LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.